Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

John­son & John­son’s Janssen said Wednes­day that its bis­pe­cif­ic an­ti­body Ry­bre­vant (ami­van­tam­ab-vmjw) in com­bo with laz­er­tinib met its dual pri­ma­ry end­points in a Phase III tri­al for pa­tients with a type of non-small cell lung can­cer.

The com­pa­ny tout­ed the re­sults as the first to show a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival in the post-Tagris­so (os­imer­tinib) set­ting. Janssen is look­ing to win over a chunk of the mar­ket cur­rent­ly held by As­traZeneca’s block­buster Tagris­so, which is the first-line treat­ment for this set­ting, and gen­er­at­ed sales of $5.4 bil­lion in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER